In parallel, numerous mAbs, including trastuzumab and pertuzumab targeting human epidermal growth factor receptor 2 (HER2), cetuximab and panitumumab targeting EGFR, and bevacizumab targeting vascular endothelial growth factor (VEGF), have been recommended for therapeutic use in conditions such as colorectal cancer, head and neck squamous cell carcinoma (HNSCC), breast cancer, and NSCLC [42–44]. Here, VEGFA is linked to non-small cell lung carcinoma.